Suppr超能文献

全国范围内多发性与首次皮肤鳞状细胞癌的发病率及皮肤鳞状细胞癌未来发病率的估计。

Incidence of Multiple vs First Cutaneous Squamous Cell Carcinoma on a Nationwide Scale and Estimation of Future Incidences of Cutaneous Squamous Cell Carcinoma.

机构信息

Department of Dermatology, Erasmus Medical Center, Rotterdam, the Netherlands.

Department of Research & Development, Netherlands Comprehensive Cancer Organization, Utrecht, the Netherlands.

出版信息

JAMA Dermatol. 2020 Dec 1;156(12):1300-1306. doi: 10.1001/jamadermatol.2020.3677.

Abstract

IMPORTANCE

Until now, most studies on cutaneous squamous cell carcinoma (cSCC) incidence rates concerned only the first cSCC per patient. Given the increase in incidence rates and the frequent occurrence of subsequent cSCCs per patient, population-based data on the incidence rates of both first and multiple cSCCs are needed.

OBJECTIVES

To calculate annual age-standardized incidence rates for histopathologically confirmed first and multiple cSCCs per patient and to estimate future cSCC incidence rates up to 2027.

DESIGN, SETTING, AND PARTICIPANTS: A nationwide population-based epidemiologic cohort study used cancer registry data on 145 618 patients with a first histopathologically confirmed cSCC diagnosed between January 1, 1989, and December 31, 2017, from the Netherlands Cancer Registry and all patients with multiple cSCCs diagnosed in 2017.

MAIN OUTCOMES AND MEASURES

Age-standardized incidence rates for cSCC-standardized to the European Standard Population 2013 and United States Standard Population 2000-were calculated per sex, age group, body site, and disease stage. A regression model with positive slope was fitted to estimate cSCC incidence rates up to 2027.

RESULTS

A total of 145 618 patients in the Dutch population (84 572 male patients [58.1%]; mean [SD] age, 74.5 [11.5] years) received a diagnosis of a first cSCC between 1989 and 2017. Based on incident data, European Standardized Rates (ESRs) increased substantially, with the highest increase found among female patients from 2002 to 2017, at 8.2% (95% CI, 7.6%-8.8%) per year. The ESRs for first cSCC per patient in 2017 were 107.6 per 100 000 person-years (PY) for male patients, an increase from 40.0 per 100 000 PY in 1989, and 68.7 per 100 000 PY for female patients, an increase from 13.9 per 100 000 PY in 1989, which corresponds with a US Standardized Rate of 71.4 per 100 000 PY in 2017 for men and 46.4 per 100 000 PY in 2017 for women. Considering multiple cSCCs per patient, ESRs increased by 58.4% for men (from 107.6 per 100 000 PY to 170.4 per 100 000 PY) and 34.8% for women (from 68.7 per 100 000 PY to 92.6 per 100 000 PY). Estimation of ESRs for the next decade show a further increase of 23.0% for male patients (ESR up to 132.4 per 100 000 PY [95% prediction interval, 125.8-139.0 per 100 000 PY]) and 29.4% for female patients (ESR up to 88.9 per 100 000 PY [95% prediction interval, 84.3-93.5 per 100 000 PY]).

CONCLUSIONS AND RELEVANCE

This nationwide epidemiologic cohort study suggests that incidence rates of cSCC keep increasing, especially among female patients, and that the occurrence of multiple cSCCs per patient significantly adds to the current and future burden on dermatologic health care. Revision of skin cancer policies are needed to halt this increasing trend.

摘要

重要性

到目前为止,大多数关于皮肤鳞状细胞癌(cSCC)发病率的研究仅涉及每位患者的首次 cSCC。鉴于发病率的增加以及每位患者随后发生的 cSCC 的频繁发生,需要基于人群的数据来了解首次和多次 cSCC 的发病率。

目的

计算每位患者首次和多次病理证实的 cSCC 的年龄标准化发病率,并估计到 2027 年的未来 cSCC 发病率。

设计、地点和参与者:一项全国性基于人群的流行病学队列研究使用了荷兰癌症登记处 1989 年 1 月 1 日至 2017 年 12 月 31 日期间诊断的 145618 例首次病理证实的 cSCC 患者以及 2017 年诊断的所有多次 cSCC 患者的癌症登记数据。

主要结果和测量

根据欧洲标准人口 2013 年和美国标准人口 2000 年进行标准化的 cSCC 年龄标准化发病率,按性别、年龄组、身体部位和疾病阶段进行计算。使用正斜率回归模型来估计到 2027 年的 cSCC 发病率。

结果

荷兰人群中共有 145618 例患者(84572 例男性患者[58.1%];平均[标准差]年龄为 74.5[11.5]岁)在 1989 年至 2017 年期间诊断出首次 cSCC。根据发病数据,欧洲标准化发病率(ESR)大幅增加,其中女性患者从 2002 年到 2017 年的增长率最高,为每年 8.2%(95%置信区间,7.6%-8.8%)。2017 年每位患者首次 cSCC 的 ESR 为男性患者 107.6/100000 人年,比 1989 年的 40.0/100000 人年增加,女性患者为 68.7/100000 人年,比 1989 年的 13.9/100000 人年增加,这与 2017 年男性患者的美国标准化发病率 71.4/100000 人年和女性患者的 46.4/100000 人年相对应。考虑到每位患者的多次 cSCC,男性患者的 ESR 增加了 58.4%(从 107.6/100000 人年增加到 170.4/100000 人年),女性患者的 ESR 增加了 34.8%(从 68.7/100000 人年增加到 92.6/100000 人年)。对未来十年 ESR 的估计显示,男性患者的发病率进一步增加 23.0%(ESR 高达 132.4/100000 人年[95%预测区间,125.8-139.0/100000 人年]),女性患者的发病率增加 29.4%(ESR 高达 88.9/100000 人年[95%预测区间,84.3-93.5/100000 人年])。

结论和相关性

这项全国性的基于人群的流行病学队列研究表明,cSCC 的发病率持续上升,尤其是在女性患者中,每位患者多次发生 cSCC 的情况显著增加了当前和未来皮肤保健的负担。需要修订皮肤癌政策以阻止这一上升趋势。

相似文献

3
Nationwide Incidence of Metastatic Cutaneous Squamous Cell Carcinoma in England.
JAMA Dermatol. 2019 Mar 1;155(3):298-306. doi: 10.1001/jamadermatol.2018.4219.
5
Epidemiology of basal and cutaneous squamous cell carcinoma in the U.K. 2013-15: a cohort study.
Br J Dermatol. 2019 Sep;181(3):474-482. doi: 10.1111/bjd.17873. Epub 2019 May 6.
7
Outcomes of Patients With Multiple Cutaneous Squamous Cell Carcinomas: A 10-Year Single-Institution Cohort Study.
JAMA Dermatol. 2015 Nov;151(11):1220-5. doi: 10.1001/jamadermatol.2015.1702.
9
Invasive and in situ squamous cell carcinoma of the skin: a nationwide study in Iceland.
Br J Dermatol. 2021 Sep;185(3):537-547. doi: 10.1111/bjd.19879. Epub 2021 May 9.
10
Incidence, mortality and trends of cutaneous squamous cell carcinoma in Germany, the Netherlands, and Scotland.
Eur J Cancer. 2023 Apr;183:60-68. doi: 10.1016/j.ejca.2023.01.017. Epub 2023 Jan 28.

引用本文的文献

1
Frequency and timing of multiple skin cancer development in five cohorts.
J Am Acad Dermatol. 2025 Jun;92(6):1295-1302. doi: 10.1016/j.jaad.2024.12.047. Epub 2025 Feb 8.
4
Toward personalized skin cancer care: multiple skin cancer development in five cohorts.
medRxiv. 2024 May 7:2024.05.06.24306947. doi: 10.1101/2024.05.06.24306947.
5
T Cell Immunity in Human Papillomavirus-Related Cutaneous Squamous Cell Carcinoma-A Systematic Review.
Diagnostics (Basel). 2024 Feb 21;14(5):473. doi: 10.3390/diagnostics14050473.
6
Epidemiology of Keratinocyte Skin Cancer with a Focus on Cutaneous Squamous Cell Carcinoma.
Cancers (Basel). 2024 Jan 31;16(3):606. doi: 10.3390/cancers16030606.
7
Targeting tumor-associated macrophages: Novel insights into immunotherapy of skin cancer.
J Adv Res. 2025 Jan;67:231-252. doi: 10.1016/j.jare.2024.01.013. Epub 2024 Jan 17.
10
Small intestinal perforation secondary to metastasis from skin squamous cell carcinoma: A case report and literature review.
Int J Surg Case Rep. 2023 Aug;109:108599. doi: 10.1016/j.ijscr.2023.108599. Epub 2023 Aug 2.

本文引用的文献

1
Epidemiology of basal and cutaneous squamous cell carcinoma in the U.K. 2013-15: a cohort study.
Br J Dermatol. 2019 Sep;181(3):474-482. doi: 10.1111/bjd.17873. Epub 2019 May 6.
2
Characteristics and Trends of Cutaneous Squamous Cell Carcinoma in a Patient Cohort in Finland 2006-2015.
Acta Derm Venereol. 2019 Apr 1;99(4):412-416. doi: 10.2340/00015555-3110.
4
Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging.
J Am Acad Dermatol. 2018 Feb;78(2):237-247. doi: 10.1016/j.jaad.2017.08.059.
5
The incidence and multiplicity rates of keratinocyte cancers in Australia.
Med J Aust. 2017 Oct 16;207(8):339-343. doi: 10.5694/mja17.00284.
6
Epidemiology of basal and squamous cell carcinoma in Belgium: the need for a uniform and compulsory registration.
J Eur Acad Dermatol Venereol. 2016 Nov;30(11):1912-1918. doi: 10.1111/jdv.13703. Epub 2016 Jun 3.
7
Outcomes of Patients With Multiple Cutaneous Squamous Cell Carcinomas.
JAMA Oncol. 2016 Jan;2(1):130-1. doi: 10.1001/jamaoncol.2015.3894.
8
Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the U.S. Population, 2012.
JAMA Dermatol. 2015 Oct;151(10):1081-6. doi: 10.1001/jamadermatol.2015.1187.
9
Cutaneous squamous cell carcinoma in Norway 1963-2011: increasing incidence and stable mortality.
Cancer Med. 2015 Mar;4(3):472-80. doi: 10.1002/cam4.404. Epub 2015 Jan 26.
10
Risk of subsequent cutaneous malignancy in patients with prior keratinocyte carcinoma: a systematic review and meta-analysis.
Eur J Cancer. 2013 Jul;49(10):2365-75. doi: 10.1016/j.ejca.2013.03.010. Epub 2013 Apr 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验